ArticleFrontiers in immunology2018
Predicting HLA CD4 Immunogenicity in Human Populations.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 141 citations in OpenAlex.
- Design of Multi-Epitope Cancer Vaccine Targeting p53 Tumor Antigen using Myotis lucifugus Sequencers: An Immunoinformatics Approach.Applied biochemistry and biotechnology · 2026Article
- Targeting Amastigote and Trypomastigote Phases: Multi-Epitope Vaccine Strategy Against Trypanosoma cruzi.Biotechnology and applied biochemistry · 2026Article
- Predicting Neoantigen Immunogenicity frombioRxiv : the preprint server for biology · 2026Article
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- Cancer epitope prediction tools and analysis pipelines in CEDAR.Nucleic acids research · 2026Article
- PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision.Bioinformatics (Oxford, England) · 2026Article
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- Transfer learning for T-cell response prediction.BMC bioinformatics · 2026Article
- Computational design and molecular characterization of a multi-epitope peptide vaccine targeting pancreatic cancer.Journal, genetic engineering & biotechnology · 2026Article
- Cytokine-driven immunogenicity prediction: integrating HLA binding and cytokine induction.Briefings in bioinformatics · 2026Article
- COMBO-RATE: An experimentally validated bioinformatic tool to identify promiscuous HLA restrictions.bioRxiv : the preprint server for biology · 2026Article
- Computational identification of conserved dengue virus envelope protein epitopes for vaccine design and immunodiagnostic platform.Scientific reports · 2026Article
- An immunoinformatic strategy for developing peptide vaccines against autoimmune diseases by targeting cross-reactive bacterial antigens.Pakistan journal of medical sciences · 2026Article
- EpiMII: Structure-Aware Graph Neural Networks for MHC-II Epitope Generation.Research (Washington, D.C.) · 2026Article
- Cut or bind? Antigen-specific processing mechanisms define CD4Genome medicine · 2025Article
- Design of a multi-epitope vaccine against drug-resistant mycobacterium tuberculosis and mycobacterium bovis using reverse vaccinology.Scientific reports · 2025Article
- Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach.Osong public health and research perspectives · 2025Article
- EpiMII: Integrating Structure and Graph Neural Networks for MHC-II Epitope and Neoantigen Design.bioRxiv : the preprint server for biology · 2025Article
- Pneumocystis Jirovecii Pneumonia: The Potential of KEX1, MSG1, and MSG2 as Key Antigens in Cytokine Release Assays.Diagnostics (Basel, Switzerland) · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundPrediction of T cell immunogenicity is a topic of considerable interest, both in terms of basic understanding of the mechanisms of T cells responses and in terms of practical applications. HLA binding affinity is often used to predict T cell epitopes, since HLA binding affinity is a key requisite for human T cell immunogenicity. However, immunogenicity at the population it is complicated by the high level of variability of HLA molecules, potential other factors beyond HLA as well as the frequent lack of HLA typing data. To overcome those issues, we explored an alternative approach to identify the common characteristics able to distinguish immunogenic peptides from non-recognized peptides.
methodsSets of dominant epitopes derived from peer-reviewed published papers were used in conjunction with negative peptides from the same experiments/donors to train neural networks and generate an "immunogenicity score." We also compared the performance of the immunogenicity score with previously described method for immunogenicity prediction based on HLA class II binding at the population level.
resultsThe immunogenicity score was validated on a series of independent datasets derived from the published literature, representing 57 independent studies where immunogenicity in human populations was assessed by testing overlapping peptides spanning different antigens. Overall, these testing datasets corresponded to over 2,000 peptides and tested in over 1,600 different human donors. The 7-allele method prediction and the immunogenicity score were associated with similar performance [average area under the ROC curve (AUC) values of 0.703 and 0.702, respectively] while the combined methods reached an average AUC of 0.725. This increase in average AUC value is significant compared with the immunogenicity score (
conclusionThe new immunogenicity score predicts CD4 T cell immunogenicity at the population level starting from protein sequences and with no need for HLA typing. Its efficacy has been validated in the context of different antigen sources, ethnicities, and disparate techniques for epitope identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.